Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of Renin–Angiotensin System Inhibitors on Mortality and Disease Severity of COVID-19 Patients: A Meta-analysis of Randomized Controlled Trials
Juntao Yin, Chaoyang Wang, Xiaoyong Song, et al.
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 462-469
Open Access | Times Cited: 18

Showing 18 citing articles:

Hypertension management before and under the COVID-19 pandemic: lessons and future directions
Yoichi Nozato, Kōichi Yamamoto, Hiromi Rakugi
Hypertension Research (2023) Vol. 46, Iss. 6, pp. 1471-1477
Open Access | Times Cited: 17
COVID-19 and metabolic syndrome
Harsha Dissanayake
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 4, pp. 101753-101753
Open Access | Times Cited: 14
Overreactive macrophages in SARS-CoV-2 infection: The effects of ACEI
Dominik Felkle, Katarzyna Zięba, Konrad Kaleta, et al.
International Immunopharmacology (2023) Vol. 124, pp. 110858-110858
Open Access | Times Cited: 8
Pharmacological therapies and drug development targeting SARS-CoV-2 infection
Yi‐Zhou Jiang, Limor Rubin, Zhiwei Zhou, et al.
Cytokine & Growth Factor Reviews (2022) Vol. 68, pp. 13-24
Open Access | Times Cited: 10
Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers and outcomes in hospitalized patients with COVID-19: an updated systematic review and meta-analysis of randomized clinical trials
Joseph Alexander Paguio, Bruce Adrian Casipit, Tara A John, et al.
Expert Review of Cardiovascular Therapy (2023) Vol. 21, Iss. 3, pp. 219-226
Closed Access | Times Cited: 5
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials
Matthew M.Y. Lee, Toru Kondo, Ross T. Campbell, et al.
European Heart Journal - Cardiovascular Pharmacotherapy (2023) Vol. 10, Iss. 1, pp. 68-80
Open Access | Times Cited: 5
Severe COVID-19 and preexisting hypertension: a matter of age?
Osamu Yamazaki, Shigeru Shibata
Hypertension Research (2022) Vol. 45, Iss. 9, pp. 1523-1525
Open Access | Times Cited: 9
Effect of the renin–angiotensin–aldosterone system inhibitors on time to nucleic acid negative conversion in hypertensive patients with SARS-CoV-2 omicron infection: a propensity score matching study
Ru Wen, Jinwen Li, Fengxi Chen, et al.
Hypertension Research (2024) Vol. 48, Iss. 1, pp. 273-283
Closed Access | Times Cited: 1
Association of Cardiovascular Medications With Adverse Outcomes in a Matched Analysis of a National Cohort of Patients With COVID-19
Leonard Kuan‐Pei Wang, Yong‐Fang Kuo, Jordan Westra, et al.
American Journal of Medicine Open (2023) Vol. 9, pp. 100040-100040
Open Access | Times Cited: 4
COVID-19 and the Use of Angiotensin II Receptor Blockers in Older Chronic Hypertensive Patients: Systematic Review and Meta-Analysis
Miguel Quesada-Caballero, Ana Carmona-García, Sara Chami-Peña, et al.
Medicina (2023) Vol. 59, Iss. 7, pp. 1200-1200
Open Access | Times Cited: 3
Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
Seiji Hamada, Tomoharu Suzuki, Yasuharu Tokuda, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 3
COVID-19 outcomes in patients taking cardioprotective medications
Fritha Morrison, Maxwell Su, Alexander Turchin
PLoS ONE (2022) Vol. 17, Iss. 10, pp. e0275787-e0275787
Open Access | Times Cited: 5
Discontinuation of Renin–Angiotensin System Inhibitors During the Early Stage of the COVID-19 Pandemic
Paul Muntner, Kathryn Foti, Zhixin Wang, et al.
American Journal of Hypertension (2023) Vol. 36, Iss. 7, pp. 404-410
Closed Access | Times Cited: 2
2023 Chinese expert consensus on the impact of COVID-19 on the management of cardiovascular diseases
Feng Bai, Jun Pu, Wenliang Che, et al.
Cardiology Plus (2023)
Open Access | Times Cited: 2
Reinventing the renin–angiotensin–aldosterone system based on experience from the COVID‐19 pandemic
Sven Kurbel
The Journal of Physiology (2024) Vol. 602, Iss. 20, pp. 5119-5124
Closed Access
Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial
Fabrice Bonnet, Adama Doumbia, Vanessa Machault, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access
Effects of Angiotensin II Receptor Blockers on the Risk of Mortality in Patients with COVID-19: An Updated Systematic Review and Meta-analysis of Randomized Trials
Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan
American Journal of Hypertension (2022) Vol. 35, Iss. 8, pp. 763-764
Open Access | Times Cited: 2
From the Editor-in-Chief: Issue at a Glance
Ernesto L. Schiffrin
American Journal of Hypertension (2022) Vol. 35, Iss. 5, pp. 377-379
Open Access
Page 1

Scroll to top